Agios Pharmaceuticals Inc (AGIO) was Reiterated by SunTrust to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 65 from a previous price target of $57 . SunTrust advised their investors in a research report released on May 18, 2016.
Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Company shares were Reiterated by Sun Trust Rbsn Humphrey on May 18, 2016 to “Buy”, Firm has raised the Price Target to $ 65 from a previous price target of $57 .Sun Trust Rbsn Humphrey Initiated Agios Pharmaceuticals Inc on Mar 30, 2016 to “Buy”, Price Target of the shares are set at $57.
On the company’s financial health, Agios Pharmaceuticals Inc reported $-0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.93. The company had revenue of $31.28 million for the quarter, compared to analysts expectations of $25.66 million. The company’s revenue was down -8.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.13 EPS.
Agios Pharmaceuticals Inc opened for trading at $46.83 and hit $50.82 on the upside on Monday, eventually ending the session at $50.57, with a gain of 8.01% or 3.75 points. The heightened volatility saw the trading volume jump to 7,50,628 shares. Company has a market cap of $1,918 M.
In a different news, on Apr 27, 2016, Lewis Clayton Jr. Cantley (director) sold 2,504 shares at $53.44 per share price. According to the SEC, on Jan 5, 2016, Scott Biller (Chief Scientific Officer) sold 5,500 shares at $65.27 per share price. On Dec 17, 2015, John Duncan Higgons (Chief Operating Officer) sold 20,000 shares at $50.09 per share price, according to the Form-4 filing with the securities and exchange commission.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.